Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer - PubMed (original) (raw)
Comparative Study
. 2007 Dec 14;131(6):1190-203.
doi: 10.1016/j.cell.2007.11.025.
Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li, Yerong Hu, Zhiping Tan, Matthew Stokes, Laura Sullivan, Jeffrey Mitchell, Randy Wetzel, Joan Macneill, Jian Min Ren, Jin Yuan, Corey E Bakalarski, Judit Villen, Jon M Kornhauser, Bradley Smith, Daiqiang Li, Xinmin Zhou, Steven P Gygi, Ting-Lei Gu, Roberto D Polakiewicz, John Rush, Michael J Comb
Affiliations
- PMID: 18083107
- DOI: 10.1016/j.cell.2007.11.025
Free article
Comparative Study
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al. Cell. 2007.
Free article
Abstract
Despite the success of tyrosine kinase-based cancer therapeutics, for most solid tumors the tyrosine kinases that drive disease remain unknown, limiting our ability to identify drug targets and predict response. Here we present the first large-scale survey of tyrosine kinase activity in lung cancer. Using a phosphoproteomic approach, we characterize tyrosine kinase signaling across 41 non-small cell lung cancer (NSCLC) cell lines and over 150 NSCLC tumors. Profiles of phosphotyrosine signaling are generated and analyzed to identify known oncogenic kinases such as EGFR and c-Met as well as novel ALK and ROS fusion proteins. Other activated tyrosine kinases such as PDGFRalpha and DDR1 not previously implicated in the genesis of NSCLC are also identified. By focusing on activated cell circuitry, the approach outlined here provides insight into cancer biology not available at the chromosomal and transcriptional levels and can be applied broadly across all human cancers.
Similar articles
- Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Haake SM, et al. Clin Cancer Res. 2016 Nov 15;22(22):5605-5616. doi: 10.1158/1078-0432.CCR-15-1673. Epub 2016 May 24. Clin Cancer Res. 2016. PMID: 27220961 Free PMC article. - The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F, Charest A. Jun HJ, et al. Cancer Res. 2012 Aug 1;72(15):3764-74. doi: 10.1158/0008-5472.CAN-11-3990. Epub 2012 Jun 1. Cancer Res. 2012. PMID: 22659450 Free PMC article. - Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M, Ott GR. Cheng M, et al. Anticancer Agents Med Chem. 2010 Mar;10(3):236-49. doi: 10.2174/1871520611009030236. Anticancer Agents Med Chem. 2010. PMID: 20406193 Review. - ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. Gridelli C, et al. Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Cancer Treat Rev. 2014. PMID: 23931927 Review.
Cited by
- The fitness cost of spurious phosphorylation.
Bradley D, Hogrebe A, Dandage R, Dubé AK, Leutert M, Dionne U, Chang A, Villén J, Landry CR. Bradley D, et al. EMBO J. 2024 Sep 10. doi: 10.1038/s44318-024-00200-7. Online ahead of print. EMBO J. 2024. PMID: 39256561 - Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non-small cell lung cancer patients.
Ma Y, Wang Y, He L, Du J, Li L, Bie Z, Li Y, Xu X, Zhou W, Wu X, Yang L, Di J, Li C, Li X, Liu D, Wang Z. Ma Y, et al. Cancer Med. 2024 Sep;13(17):e70197. doi: 10.1002/cam4.70197. Cancer Med. 2024. PMID: 39233657 Free PMC article. - The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions.
Rina A, Maffeo D, Minnai F, Esposito M, Palmieri M, Serio VB, Rosati D, Mari F, Frullanti E, Colombo F. Rina A, et al. Cancers (Basel). 2024 Aug 19;16(16):2882. doi: 10.3390/cancers16162882. Cancers (Basel). 2024. PMID: 39199653 Free PMC article. Review. - Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H, Croce CM. Tomuleasa C, et al. Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w. Signal Transduct Target Ther. 2024. PMID: 39138146 Free PMC article. Review. - FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
Barbato MI, Bradford D, Ren Y, Aungst SL, Miller CP, Pan L, Zirkelbach JF, Li Y, Bi Y, Fan J, Grimstein M, Dorff SE, Amatya AK, Mishra-Kalyani PS, Scepura B, Schotland P, Udoka O, Ojofeitimi I, Leighton JK, Rahman NA, Pazdur R, Singh H, Kluetz PG, Drezner N. Barbato MI, et al. Clin Cancer Res. 2024 Aug 15;30(16):3364-3370. doi: 10.1158/1078-0432.CCR-24-0949. Clin Cancer Res. 2024. PMID: 38875108
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous